Skip to main content

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Publication ,  Journal Article
Gromeier, M; Brown, MC; Zhang, G; Lin, X; Chen, Y; Wei, Z; Beaubier, N; Yan, H; He, Y; Desjardins, A; Herndon, JE; Varn, FS; Verhaak, RG ...
Published in: Nat Commun
January 13, 2021

Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy intervention. We report that very low tumor mutation burden is associated with longer survival after recombinant polio virotherapy or after immune checkpoint blockade in recurrent glioblastoma patients. A relationship between tumor mutation burden and survival is not observed in cohorts of immunotherapy naïve newly diagnosed or recurrent glioblastoma patients. Transcriptomic analyses reveal an inverse relationship between tumor mutation burden and enrichment of inflammatory gene signatures in cohorts of recurrent, but not newly diagnosed glioblastoma tumors, implying that a relationship between tumor mutation burden and tumor-intrinsic inflammation evolves upon recurrence.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

January 13, 2021

Volume

12

Issue

1

Start / End Page

352

Location

England

Related Subject Headings

  • Survival Analysis
  • Proportional Hazards Models
  • Outcome Assessment, Health Care
  • Oncolytic Virotherapy
  • Neoplasm Recurrence, Local
  • Mutation
  • Inflammation
  • Immunotherapy
  • Humans
  • Glioblastoma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gromeier, M., Brown, M. C., Zhang, G., Lin, X., Chen, Y., Wei, Z., … Ashley, D. M. (2021). Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun, 12(1), 352. https://doi.org/10.1038/s41467-020-20469-6
Gromeier, Matthias, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.Nat Commun 12, no. 1 (January 13, 2021): 352. https://doi.org/10.1038/s41467-020-20469-6.
Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, et al. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun. 2021 Jan 13;12(1):352.
Gromeier, Matthias, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.Nat Commun, vol. 12, no. 1, Jan. 2021, p. 352. Pubmed, doi:10.1038/s41467-020-20469-6.
Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon JE, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Lipp ES, Nair SK, Khasraw M, Peters KB, Randazzo D, Sampson JH, McLendon RE, Bigner DD, Ashley DM. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun. 2021 Jan 13;12(1):352.

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

January 13, 2021

Volume

12

Issue

1

Start / End Page

352

Location

England

Related Subject Headings

  • Survival Analysis
  • Proportional Hazards Models
  • Outcome Assessment, Health Care
  • Oncolytic Virotherapy
  • Neoplasm Recurrence, Local
  • Mutation
  • Inflammation
  • Immunotherapy
  • Humans
  • Glioblastoma